Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study)

Sofia Tzoumpa; Saskia Ingen-Housz-Oro; Adele de Masson; Anne Pham-Ledard; Tarik El Aarbaoui; Olivier Dereure; Gaelle Quereux; Sarah Faiz; Marine de Vicq de Cumptich; Caroline Ram-Wolff; Raphael Janela-Lapert; Emmanuella Guenova; Coralie Lheure; Yannick Le Corre; Henri Adamski; Mael Blanchard; Nathalie Bonnet; Florent Amatore; Florent Grange; Laura Troin; Martine Bagot; Marie Beylot-Barry

doi:10.1093/bjd/ljae153

Retour

Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study)

Article de revue

Avec comité de lecture

Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study)

Sofia Tzoumpa, Saskia Ingen-Housz-Oro, Adele de Masson, Anne Pham-Ledard, Tarik El Aarbaoui, Olivier Dereure, Gaelle Quereux, Sarah Faiz, Marine de Vicq de Cumptich, Caroline Ram-Wolff, …

British journal of dermatology (1951), Vol.191(1), pp.143-144

20/06/2024

DOI: https://doi.org/10.1093/bjd/ljae153

PMID: 38660811

Résumé

Dermatology

Life Sciences & Biomedicine

Science & Technology

The results of this study suggest that progressive discontinuation of mogamulizumab (Moga) should be considered once a response is obtained in patients with S & eacute;zary syndrome, even after a short treatment duration. This may minimize the risk of adverse effects, costs and resistance to Moga. Additionally, our study emphasizes that Moga rechallenge should be encouraged as a first choice in relapsing patients.

Indicateurs

1 Consultations de la notice

Détails

Titre: Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study)
Créateurs - sans rôle: Sofia Tzoumpa - Henri Mondor Univ Hosp, AP HP, Dept Dermatol, Creteil, France
Saskia Ingen-Housz-Oro - Henri Mondor Univ Hosp, AP HP, Dept Dermatol, Creteil, France
Adele de Masson - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Anne Pham-Ledard - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Tarik El Aarbaoui - Paris Est Creteil Univ, EpiDermE, Creteil, France
Olivier Dereure - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Gaelle Quereux - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Sarah Faiz - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Marine de Vicq de Cumptich - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Caroline Ram-Wolff - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Raphael Janela-Lapert - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Emmanuella Guenova - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Coralie Lheure - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Yannick Le Corre - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Henri Adamski - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Mael Blanchard - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Nathalie Bonnet - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Florent Amatore - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Florent Grange - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Laura Troin - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Martine Bagot - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Marie Beylot-Barry - French Cutaneous Lymphomas Study Grp GFELC, Paris, France
Détails de publication: British journal of dermatology (1951), Vol.191(1), pp.143-144
Éditeur: Oxford Univ Press
Nombre de pages: 2
Identifiants: 99157080909311
Unité académique: Pathogenesis and Control of Chronic and Emerging Infections - PCCEI
Langue: English
Type de ressource: Journal article